Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03789656 · ClinicalTrials.gov registry record · Phase 2
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
A Phase 2 study, sponsored by Crinetics Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT03789656 is a Phase 2 study that has completed, run by Crinetics Pharmaceuticals. The registered enrollment target is 47 participants.
The verdict
NCT03789656, a Phase 2 study, has completed, sponsored by Crinetics Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
An open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are treated with somatostatin analogue (SSA) based treatment regimens.
Interventions
- DRUG Paltusotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2019-03-12 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03789656
The ClinicalTrials.gov registry entry for NCT03789656 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crinetics Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paltusotine is the first listed.
NCT03789656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03789656 about?
NCT03789656 is a clinical study titled "An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)". An open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are treated with somatostatin analogue (SSA) based treatment regimens.
What is the current status of trial NCT03789656?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2019-03-12. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT03789656?
The interventions under investigation include: Paltusotine (DRUG).
Who is sponsoring clinical trial NCT03789656?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.